Literature DB >> 11465929

Cognitive impairment in motor neuron disease with bulbar onset.

F Portet1, C Cadilhac, J Touchon, W Camu.   

Abstract

METHODS: Twenty-three patients with bulbar onset motor neuron disease/amyotrophic lateral sclerosis (MND/ALS) were clinically assessed. They subsequently underwent serial neuropsychological testing, event-related potentials (ERP) and SPECT studies. Cognitive impairment was defined by clinical evidence of dementia (DSM-IV and frontal evaluation) or by significant alteration indicated by neuropsychological testing (excluding patients with depression and major anxiety), or both.
RESULTS: Eleven patients (48%) were found to be cognitively impaired. Abnormalities indicated fronto-temporal involvement, with memory impairment, alteration of judgement and reasoning, reduced speech, behavioural dyscontrol and alteration of daily living activities. This impairment correlated well with event-related potentials and SPECT studies. Event-related potentials were the most sensitive test as 100% of the impaired patients had abnormal ERP (p = 0.04). The cognitively impaired group differed from the other group mainly by gender ratio (male/female) with an important male predominance: 1.75 vs. 0.33. MND/ALS was also more severe when cognitive decline was present.
CONCLUSION: This study adds further arguments for a cognitive impairment in MND/ALS. This also reinforces the hypothesis that there is continuum between MND/ALS and fronto-temporal lobe dementia.

Entities:  

Mesh:

Year:  2001        PMID: 11465929     DOI: 10.1080/146608201300079382

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  15 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 2.  Neurophysiological markers of network dysfunction in neurodegenerative diseases.

Authors:  Roisin McMackin; Peter Bede; Niall Pender; Orla Hardiman; Bahman Nasseroleslami
Journal:  Neuroimage Clin       Date:  2019-02-02       Impact factor: 4.881

Review 3.  Frontotemporal dementia: a bridge between dementia and neuromuscular disease.

Authors:  Adeline S L Ng; Rosa Rademakers; Bruce L Miller
Journal:  Ann N Y Acad Sci       Date:  2014-12-30       Impact factor: 5.691

Review 4.  The neuropathological signature of bulbar-onset ALS: A systematic review.

Authors:  S Shellikeri; V Karthikeyan; R Martino; S E Black; L Zinman; J Keith; Y Yunusova
Journal:  Neurosci Biobehav Rev       Date:  2017-02-02       Impact factor: 8.989

5.  Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients.

Authors:  Herbert Schreiber; Tanja Gaigalat; Ursula Wiedemuth-Catrinescu; Michael Graf; Ingo Uttner; Rainer Muche; Albert Christian Ludolph
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

Review 6.  ALS and FTLD: two faces of TDP-43 proteinopathy.

Authors:  R M Liscic; L T Grinberg; J Zidar; M A Gitcho; N J Cairns
Journal:  Eur J Neurol       Date:  2008-08       Impact factor: 6.089

7.  Depression and quality of life issues in patients with amyotrophic lateral sclerosis.

Authors:  Shannon F Stromberg; David B Weiss
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

Review 8.  Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jessica Root; Paola Merino; Austin Nuckols; Michelle Johnson; Thomas Kukar
Journal:  Neurobiol Dis       Date:  2021-03-31       Impact factor: 7.046

9.  ALS and Frontotemporal Dysfunction: A Review.

Authors:  Eugene Y Achi; Stacy A Rudnicki
Journal:  Neurol Res Int       Date:  2012-08-07

Review 10.  Assessment of multifunctional contrast agent probes in neuroimaging: Implications of nanopharmaceutical therapeutic interventions.

Authors:  Lina H Machtoub
Journal:  J Adv Pharm Technol Res       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.